1-7 of 7
Niels W. C. J. van de Donk, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-133873
Published: 2020
Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Niels W. C. J. Van De Donk, MD PhD, Bronno van der Holt, PhD, Fredrik H. Schjesvold, MD PhD, Ka Lung Wu, MD, Stefano Spada, Annemiek Broyl, MD PhD, Wilfried Roeloffzen, Alain Gaddiseur, Thomas Lund, MD, Monique C. Minnema, Massimo Offidani, Mariella Grasso, Niels Frost Andersen, Jo Caers, MD PhD, Benedetto Bruno, MD, Sonja Zweegman, MD PhD, Pieter Sonneveld, Roman Hajek, Prof, MD PhD, Reuben Benjamin, MD, Francesca Gay, MD, Annette Juul Vangsted, MD PhD, Pellegrino Musto
Journal: Blood
Blood (2019) 134 (Supplement_1): 693.
https://doi.org/10.1182/blood-2019-125120
Published: 2019
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, Ellen van der Spek, MD PhD, Roel J.W. Van Kampen, MD PhD, Maaike Sohne, MD, Noortje Thielen, MD PhD, Yavuz Bilgin, MD PhD, Esther G.M. De Waal, MD, Inge Ludwig, MD MSc, Maria B.L. Leijs, MD, Alain Kentos, MD, Gert Jan Timmers, MD PhD, Koen de Heer, MD, Matthijs Westerman, MD, Marie Christiane Vekemans, Nazik Durdu-Rayman, MD, Nicole C.H.P. van der Burg-de Graauw, MD, Niels W. C. J. Van De Donk, MD PhD, Pieter Sonneveld, Saskia K. Klein, MD PhD, Mark-David Levin, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 695.
https://doi.org/10.1182/blood-2019-121694
Published: 2019
Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1879.
https://doi.org/10.1182/blood-2019-124339
Published: 2019
Journal Articles

Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study

Kristine A. Frerichs, MD, Monique C. Minnema, Mark-David Levin, MD PhD, Annemiek Broyl, MD PhD, Gerard Bos, MD PhD, Marie José Kersten, MD PhD, Tuna Mutis, Christie P.M. Verkleij, MD, Patricia W.C. Bosman, MSc, Saskia K. Klein, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, Niels W. C. J. Van De Donk, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1826.
https://doi.org/10.1182/blood-2019-123383
Published: 2019
Journal Articles

The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression

Michel Delforge, MD PhD, Philippe Moreau, MD, Maria-Victoria Mateos, Valerio De Stefano, MD, Katja Weisel, Jesús San-Miguel, Hermann Einsele, MD, Thierry Facon, MD, Mario Boccadoro, Hartmut Goldschmidt, Michele Cavo, Laura Rosinol, MD PhD, Martin F. Kaiser, Francesca Gay, MD, Christof Scheid, MD, Annemiek Broyl, MD PhD, Niels W. C. J. Van De Donk, MD PhD, Paula Rodriguez, MD, Anna Potamianou, Caline Sakabedoyan, Vadim Strulev, Tonia Nesheiwat, Paul Bergmans, Syed Rizvi, MD, Arkadiusz Pilatowicz, Pieter Sonneveld
Journal: Blood
Blood (2019) 134 (Supplement_1): 5549.
https://doi.org/10.1182/blood-2019-122939
Published: 2019
Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn
Journal: Blood
Blood (2019) 134 (Supplement_1): 3106.
https://doi.org/10.1182/blood-2019-125788
Published: 2019